Janux Therapeutics, Inc.
JANX
$17.11
$1.257.88%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -23.37% | -97.10% | 28.12% | 30.99% | 54.12% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -23.37% | -97.10% | 28.12% | 30.99% | 54.12% |
| Cost of Revenue | 74.04% | 26.26% | -9.21% | -32.18% | -50.64% |
| Gross Profit | -155.33% | -107.12% | 15.14% | 43.08% | 68.51% |
| SG&A Expenses | -0.14% | 65.17% | 61.17% | 57.03% | 53.92% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 55.83% | 79.27% | 53.37% | 35.00% | 18.47% |
| Operating Income | -67.85% | -119.74% | -55.89% | -35.45% | -14.45% |
| Income Before Tax | -68.32% | -139.85% | -39.84% | -18.36% | 3.30% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -68.32% | -139.85% | -39.84% | -18.36% | 3.30% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -68.32% | -139.85% | -39.84% | -18.36% | 3.30% |
| EBIT | -67.85% | -119.74% | -55.89% | -35.45% | -14.45% |
| EBITDA | -69.54% | -123.60% | -57.48% | -36.27% | -14.47% |
| EPS Basic | -42.46% | -96.30% | -11.00% | 4.61% | 20.33% |
| Normalized Basic EPS | -42.45% | -96.28% | -11.00% | 4.62% | 20.34% |
| EPS Diluted | -42.46% | -96.30% | -11.00% | 4.61% | 20.33% |
| Normalized Diluted EPS | -42.45% | -96.28% | -11.00% | 4.62% | 20.34% |
| Average Basic Shares Outstanding | 18.42% | 20.04% | 24.24% | 22.14% | 19.85% |
| Average Diluted Shares Outstanding | 18.42% | 20.04% | 24.24% | 22.14% | 19.85% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |